Major advances in our understanding of the molecular pathogenesis of non-small-cell lung cancer (NSCLC) have led to effective targeted therapeutics in several genomically-defined subsets of NSCLC. The recently updated College of American Pathologists, International Association for the Study of Lung cancer, and Association for Molecular Pathology joint guideline, which was endorsed by ASCO, sets new standards for molecular testing in NSCLC.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis
Cancer Cell International Open Access 01 February 2021
-
Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment
Cancer Cell International Open Access 27 November 2020
-
DRAM1 plays a tumor suppressor role in NSCLC cells by promoting lysosomal degradation of EGFR
Cell Death & Disease Open Access 17 September 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
Kris, M. G. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998–2006 (2014).
Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017).
Diaz, L. A. Jr & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014).
Lindeman, N. I. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J. Thorac. Oncol 13, 323–358 (2018).
Kalemkerian, G. P. et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J. Clin Oncol. 36, 911–919 (2018).
Oxnard, G. R. et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 3375–3382 (2016).
Hyman, D. M., Taylor, B. S. & Baselga, J. Implementing genome-driven oncology. Cell 168, 584–599 (2017).
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).
Vargas, A. J. & Harris, C. C. Biomarker development in the precision medicine era: lung cancer as a case study. Nat. Rev. Cancer 16, 525–537 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kim, C., Giaccone, G. Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nat Rev Clin Oncol 15, 348–349 (2018). https://doi.org/10.1038/s41571-018-0008-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0008-0
This article is cited by
-
LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis
Cancer Cell International (2021)
-
Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment
Cancer Cell International (2020)
-
DRAM1 plays a tumor suppressor role in NSCLC cells by promoting lysosomal degradation of EGFR
Cell Death & Disease (2020)
-
The lung microenvironment: an important regulator of tumour growth and metastasis
Nature Reviews Cancer (2019)